Ozone Treatment Protocol for Recurrent Urinary Infections

Background

Recurrent urinary tract infections (UTIs) are a common and often frustrating problem, particularly for women, who can face repeated episodes despite courses of antibiotics. Rising antibiotic resistance has driven interest in adjunct or alternative approaches, and some ozone therapy practitioners have proposed medical ozone - a reactive gas mixture of oxygen and ozone - as one such option, based on its antimicrobial and immune-modulating properties described in the wider ozone therapy literature.

This document is a clinical protocol issued by AEPROMO (the Spanish association of medical ozone therapy specialists), dated April 2016, developed within the framework of the Madrid Declaration on Ozone Therapy (ISCO3, 2nd edition, 2015). It sets out procedural guidance for AEPROMO member physicians on administering ozone for recurrent UTIs. It is a working practice guideline, not a report of a clinical study.

Study design

This is not a clinical trial, case series, or observational study with patient data - it is a procedural protocol. It does not describe a study population, sample size, control group, or outcome measures. Instead, it sets out two delivery methods for physicians to use in practice:

• Ozone gas insufflation: introducing ozone gas directly into the bladder via a thin, pre-lubricated silicone catheter, at a concentration of 10-15 micrograms per normal millilitre (µg/NmL), in a 100 mL volume.
• Ozonated water instillation: instilling 100 mL of ozonated bidistilled water at 5 µg/NmL into the bladder, removing 50 mL and leaving 50 mL inside.
• For associated urethral stenosis, a separate, lower-dose insufflation (8 µg/NmL, 20 mL volume) is suggested once or twice weekly.

The document does not explain how these parameters were derived, and it does not cite supporting trial data within the text itself.

Findings

Because this is a procedural protocol rather than a research study, it does not report findings, patient outcomes, infection clearance rates, or any comparative data. No results are presented in the document.

What the authors concluded

AEPROMO does not present a research conclusion here. The document's purpose is to standardise how member physicians deliver ozone to the bladder for recurrent UTIs and related urethral stenosis, framed as practice guidance consistent with the Madrid Declaration on Ozone Therapy, rather than as evidence drawn from a specific study.

Limitations of this study

This is a professional association protocol, not a peer-reviewed clinical trial or case series. It carries no named individual authors, no journal publication, no DOI, no patient sample, and no reported outcome data, so it cannot be used to judge how effective ozone therapy is for recurrent UTIs in practice. The dosing figures reflect AEPROMO's internal clinical guidance for its members rather than data verified through independent, controlled research. It should be read as a description of how some ozone therapy practitioners administer treatment, not as evidence of clinical efficacy.